Non-depolarizing muscle relaxants are excreted mainly unchanged by the kidneys. Fazadinium is more rapidly eliminated from the body than other non-depolarizing relaxants despite its relatively small urinary excretion accounting for only 50% of the dose administered (Duvaldestin et al., 1979) . It has been suggested, therefore, that biliary excretion may represent an important supplementary pathway of elimination for fazadinium in man. This is further supported by the minor pharmacokinetic alterations observed in patients with complete renal failure (Duvaldestin et al., 1979) . The influence of two different types of liver disease, namely cirrhosis and extrahepatic cholestasis, on the pharmacokinetics of fazadinium was investigated in the present study.
METHODS
Eight patients with cirrhosis and eight patients with total biliary obstruction undergoing abdominal surgery were investigated during anaesthesia. The characteristics of the patients and the surgical procedures are listed in table I. At the time of surgery, none of the patients had clinical evidence of ascites or oedema. Liver function tests (table II) consisted of the measurement of total serum bilirubin and plasma protein concentrations, serum transaminase and alkaline phosphatase concentrations, and prothrombin time. Patients with cholestasis were treated with vitamin K x before surgery. None of the patients with liver disease had biological evidence of impairment of renal function. These patients were compared with a group of patients free from liver disease undergoing general anaesthesia for elective abdominal surgery, described in a previous report (Duvaldestin et al., 1979) .
The same anaesthetic procedure was used for all patients. Premedication consisted of atropine 0.5 mg and droperidol 5-15 mg given i.m. or of diazepam 5-15 mg given orally. Anaesthesia was induced with thiopentone 5-7 mg kg" 1 and maintained with 33% oxygen in a nitrous oxide mixture delivered by mechanical ventilation. Suxamethonium 0.8 mg kg" 1 was given i.v. to facilitate tracheal intubation. Phenoperidine or fentanyl was given in repeated doses. Fazadinium was injected i.v. in a single dose of 1, 1.5 or Zmgkg" 1 , according to the duration of operation, which varied from 150 to 400 min. Serial blood samples were obtained from the 5th to the 360th min after injection of fazadinium. Urine samples were collected from patients with an indwelling catheter, 3, 6 and 24 h after administration of the drug. The concentration of faTflriininm in serum or urine was measured fluorimetrically (Pastorino, 1978) . The phannacokinetics of fazadinium were analysed according to a two-compartment open model described in detail in a previous report (Duvaldestin, Henzel et al., 1978) . Pharmacokinetic parameters were computed using an identification algorithm (Richalet, Rault and Pouliquen, 1971) which minimizes an error criterion between the observed values and those obtained by simulation of a two-compartment open model. Twotailed Student's t tests were used to evaluate the differences between the groups of patients.
RESULTS
The pharmacokinetic variables are presented in table III. A slower rate of disappearance of fazadinium from the plasma was observed in patients with liver disease ( fig. 1 ). In patients with cirrhosis, both the distribution and elimination half-lives were prolonged (table IV) . Tf and T/ were increased by 90% from 10.2 to 18.9 min and from 82 to 153 min respectively. No significant increase in the plasma clearance of fazadinium was observed in patients with cirrhosis, whereas these patients exhibited a marked increase (56%) in the total apparent volume of distribution, from 0.287 to 0.448 litre kg" 1 . The increase in both the central volume, V x and in the peripheral volume of distribution, V t (table III) , contributed to the increase in V. Urinary excretion of fazadinium was diminished in patients with drrhosis, 3, 6 and 24 h after its administration (table V) .
In patients with cholestasis, only minor modifications of fazadinium pharmacokinetics were observed. Tf was not modified and Tf was only slightly increased from 82 min to 103 min. The decrease of plasma clearance from 96 to 82 ml min" 1 m~2 was not significant and was less pronounced than in patients with cirrhosis. V was not modified but V 2 was increased by about 40% (table III) . In three patients with cholestasis the serum concentration of metabolites was also determined. The concentrations of metabolites never exceeded 3% of the total plasma concentration and were comparable to values observed in control patients (Duvaldestin et al., 1979) .
DISCUSSION
Previous pharmacokinetic studies have suggested that a substantial fraction of the dose of fazadinium could be excreted by the liver. Compared with other non-depolarizing relaxants, fazadinium presents the following properties: (1) it disappears more rapidly from the plasma with an elimination half-life of 80 min instead of 120 min or more for other agents; (2) its cumulative urinary excretion accounts for only 50% of the dose, which is relatively similar to pancuronium excretion (Agoston et al., 1973) . However, when urine was collected accurately via an indwelling catheter we found greater values averaging 65-70% of the dose of pancuronium administered for 24 h urinary excretion. Cumulative urinary excretion accounted for approximately 80% of the dose of alcuronium (Raaflaub and Frey, 1972) and gallamine (Agoston et al., 1978) ; (3) its pharmacokinetics are less altered by renal failure than is the case for tubocurarine and pancuronium (Duvaldestin et al., 1979) . The weight of this evidence supports the hypothesis of an extrarenal pathway of elimination. The liver disposition of fazadinium consists of biotransformation or biliary excretion. Inactivation through splitting of fazadinium by microsomal azoreductase does not represent a substantial fraction of the dose of fazadinium present in plasma and urine in man (Duvaldestin et al., 1979) .
Biliary excretion represents an accessory pathway of excretion for most non-depolarizing muscle relaxants. Approximately 10% of the dose is excreted in the bile in the case of alcuronium (Raaflaub and Frey, 1972) , tubocurarine (Meijer et al., 1979) and pancuronium (Agoston et al., 1973) . This percentage is even less for dimethyl-d-tubocurarine (Meijer et al., 1979) and negligible for gallamine (Agoston et al., 1978) . Greater binary excretion of fazadinium, accounting for 20-40% of the dose administered, was expected from previous studies. However, the results of the present study suggest that the role of the liver in the disposition of fazadinium is less important than anticipated.
In cirrhosis, prolongation of the elimination halflife is solely a result of increased volume of distribution. In these patients no significant change of plasma clearance was observed and the delayed urinary, elimination can also be explained by an increase in V.
More surprising was the absence of important pharmacokinetic changes in patients with extrahepatic cholestasis. In all patients studied, obstruction of the common bile duct was complete but had little effect on the profile of decline of the blood concentration. Neither the elimination half-life nor the plasma clearance were modified significantly in these patients. The reasons for there being no decrease in clearance in patients with liver diseases of both parenchymal and ductal types remain unclear.
Renal excretion was not compensating for the absence of hepatic excretion in patients with cirrhosis. In patients with cholestasis, however, urine was sampled in only two patients and increased compensatory renal excretion remains a possible mechanism of rapid excretion. By comparison, the pharmacokinetic alterations observed for pancuronium are more pronounced, especially for patients with cholestasis in whom the elimination half-life was prolonged by 100% compared with normal patients (Somogyi, Shanks and Triggs, 1977) . This change corresponded to a decrease of plasma clearance which cannot be attributed solely to a defect in biliary excretion, the latter accounting for only 10% of the elimination of pancuronium.
The pharmacokinetic alterations associated with liver cirrhosis are similar for fazadinium and pancuronium and correspond essentially to an increase in V, whereas the direct influence of liver failure is negligible as suggested by the minor decrease of pancuronium clearance (Duvaldestin, Agoston et al., 1978) and unchanged faTflHininm clearance.
From the present study it is concluded that liver disease will have only little influence on the duration of action of fazadinium. The absence of prolongation of the elimination half-life in cholestatic patients argues against substantial excretion of fazadinium in the bile. Another extrarenal pathway of elimination, which has not yet been demonstrated, remains a possible mechanism for the rapid disappearance of fazadinium from the body.
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